Company intelligence / Profile preview

Elro Pharma

Ownership: Private
Development stage: Other

Overview

Elro Pharma Sarl was a French biotech subsidiary of ImmuPharma focused on the Nucant peptide-based cancer program. In 2019, it was merged with Ureka Sarl to combine their technologies into a single platform company aimed at attracting external investment. The main asset was a drug candidate in clinical development targeting oncology indications.

Therapeutic areas: Oncology
Modalities: PeptidesSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Elro Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elro Pharma.

Explore the full profile